These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial. Lindesmith LC; Ferris MT; Mullan CW; Ferreira J; Debbink K; Swanstrom J; Richardson C; Goodwin RR; Baehner F; Mendelman PM; Bargatze RF; Baric RS PLoS Med; 2015 Mar; 12(3):e1001807. PubMed ID: 25803642 [TBL] [Abstract][Full Text] [Related]
5. Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial. Leroux-Roels G; Cramer JP; Mendelman PM; Sherwood J; Clemens R; Aerssens A; De Coster I; Borkowski A; Baehner F; Van Damme P J Infect Dis; 2018 Jan; 217(4):597-607. PubMed ID: 29140444 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of a bivalent virus-like particle norovirus vaccine in children from 1 to 8 years of age: A phase 2 randomized, double-blind study. Vesikari T; Saez-Llorens X; Blazevic V; Lopez P; Lopez E; Masuda T; Mendelman PM; Liu M; Sherwood J; Baehner F; Borkowski A Vaccine; 2022 Jun; 40(26):3588-3596. PubMed ID: 35595661 [TBL] [Abstract][Full Text] [Related]
7. A phase 2 study of the bivalent VLP norovirus vaccine candidate in older adults; impact of MPL adjuvant or a second dose. Treanor J; Sherwood J; Cramer JP; Le Cam Bouveret N; Lin S; Baehner F; Borkowski A; Vaccine; 2020 Aug; 38(36):5842-5850. PubMed ID: 32563606 [TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity studies in animal models support clinical development of a bivalent norovirus-like particle vaccine produced in plants. Tusé D; Malm M; Tamminen K; Diessner A; Thieme F; Jarczowski F; Blazevic V; Klimyuk V Vaccine; 2022 Feb; 40(7):977-987. PubMed ID: 35063285 [TBL] [Abstract][Full Text] [Related]
14. Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypes. Malm M; Tamminen K; Heinimäki S; Vesikari T; Blazevic V Vaccine; 2018 Jan; 36(4):484-490. PubMed ID: 29246474 [TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial. Kim L; Liebowitz D; Lin K; Kasparek K; Pasetti MF; Garg SJ; Gottlieb K; Trager G; Tucker SN JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997294 [TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations. Parra GI; Bok K; Taylor R; Haynes JR; Sosnovtsev SV; Richardson C; Green KY Vaccine; 2012 May; 30(24):3580-6. PubMed ID: 22469864 [TBL] [Abstract][Full Text] [Related]
18. Combination of three virus-derived nanoparticles as a vaccine against enteric pathogens; enterovirus, norovirus and rotavirus. Heinimäki S; Hankaniemi MM; Sioofy-Khojine AB; Laitinen OH; Hyöty H; Hytönen VP; Vesikari T; Blazevic V Vaccine; 2019 Dec; 37(51):7509-7518. PubMed ID: 31585726 [TBL] [Abstract][Full Text] [Related]
19. Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults. Bernstein DI; Atmar RL; Lyon GM; Treanor JJ; Chen WH; Jiang X; Vinjé J; Gregoricus N; Frenck RW; Moe CL; Al-Ibrahim MS; Barrett J; Ferreira J; Estes MK; Graham DY; Goodwin R; Borkowski A; Clemens R; Mendelman PM J Infect Dis; 2015 Mar; 211(6):870-8. PubMed ID: 25210140 [TBL] [Abstract][Full Text] [Related]
20. 6-Valent Virus-Like Particle-Based Vaccine Induced Potent and Sustained Immunity Against Noroviruses in Mice. Hou W; Lv L; Wang Y; Xing M; Guo Y; Xie D; Wei X; Zhang X; Liu H; Ren J; Zhou D Front Immunol; 2022; 13():906275. PubMed ID: 35711416 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]